5. Ultragenyx Pharmaceutical (NASDAQ:RARE)
Upside Potential: 160.3%
Ultragenyx Pharmaceutical (NASDAQ: RARE) ranks fifth in our list of the 10 biotechnology stocks with more than 50% upside potential, and the company has long been known among investors as one of the most dedicated developers of therapies for rare and ultra-rare genetic diseases. Founded with the mission of addressing conditions often overlooked by larger pharmaceutical companies, Ultragenyx has built a pipeline of treatments targeting diseases with extremely limited or nonexistent treatment options.
The company’s research strategy focuses heavily on gene therapy and advanced biologic medicines, with several programs progressing through various stages of clinical development. Analysts remain particularly interested in the progress of UX111, a therapy targeting Sanfilippo syndrome type A, a rare and devastating neurological disease affecting children. Recent updates indicate that the company is preparing a Biologics License Application resubmission, supported by extended clinical data showing sustained neurological improvements and positive biomarker responses.
H.C. Wainwright analyst Ram Selvaraju recently reiterated his Buy rating on Ultragenyx while setting a price target of $60 per share. His outlook reflects confidence in the company’s clinical pipeline as well as its potential to achieve profitability within the next few years. In addition, Barclays analyst Eliana Merle initiated coverage with an Overweight rating, pointing to a potentially improving outlook for biotech stocks supported by strong industry fundamentals and continued merger-and-acquisition activity across the pharmaceutical sector.
For investors evaluating rare disease biotech companies and gene therapy stocks, Ultragenyx represents a long-term growth story built around innovative science and a pipeline designed to address serious unmet medical needs.
Click next to see the following stock...
